Hims & Hers Health, Inc. (NYSE:HIMS) Shares Sold by BIT Capital GmbH

BIT Capital GmbH lessened its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 80.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,529,544 shares of the company’s stock after selling 6,171,360 shares during the period. Hims & Hers Health accounts for approximately 2.9% of BIT Capital GmbH’s investment portfolio, making the stock its 14th biggest holding. BIT Capital GmbH owned approximately 0.70% of Hims & Hers Health worth $36,984,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Crewe Advisors LLC acquired a new position in Hims & Hers Health in the fourth quarter valued at $28,000. Raleigh Capital Management Inc. lifted its holdings in shares of Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 1,100 shares during the last quarter. Blume Capital Management Inc. boosted its position in shares of Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 600 shares during the period. Smartleaf Asset Management LLC grew its stake in Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock worth $36,000 after buying an additional 1,413 shares during the last quarter. Finally, US Bancorp DE grew its stake in Hims & Hers Health by 346.7% during the 4th quarter. US Bancorp DE now owns 1,943 shares of the company’s stock worth $47,000 after buying an additional 1,508 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Insider Activity

In other Hims & Hers Health news, insider Soleil Boughton sold 268,932 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $27.75, for a total value of $7,462,863.00. Following the completion of the transaction, the insider now directly owns 169,803 shares of the company’s stock, valued at approximately $4,712,033.25. This trade represents a 61.30 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Patrick Harrison Carroll sold 23,287 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $34.31, for a total transaction of $798,976.97. Following the sale, the insider now owns 209,661 shares of the company’s stock, valued at approximately $7,193,468.91. The trade was a 10.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 994,031 shares of company stock worth $35,536,180 in the last 90 days. 17.71% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Citigroup reissued a “sell” rating and issued a $27.00 price objective on shares of Hims & Hers Health in a report on Thursday, March 6th. Canaccord Genuity Group raised their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, February 19th. Bank of America lifted their price objective on shares of Hims & Hers Health from $21.00 to $22.00 and gave the company an “underperform” rating in a research note on Tuesday, March 18th. Truist Financial increased their target price on shares of Hims & Hers Health from $24.00 to $39.00 and gave the stock a “hold” rating in a research note on Wednesday, February 26th. Finally, Morgan Stanley cut Hims & Hers Health from an “overweight” rating to an “equal weight” rating and boosted their price target for the company from $42.00 to $60.00 in a research report on Tuesday, February 18th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Hims & Hers Health currently has a consensus rating of “Hold” and a consensus price target of $37.31.

Hims & Hers Health Trading Down 9.8 %

NYSE HIMS opened at $33.39 on Thursday. The stock has a market capitalization of $7.42 billion, a price-to-earnings ratio of 75.90 and a beta of 1.37. The business’s 50 day moving average is $39.77 and its two-hundred day moving average is $29.25. Hims & Hers Health, Inc. has a 12-month low of $11.20 and a 12-month high of $72.98.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. Equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.